In a community study of 700 men, 43 percent of those who had both obstructive sleep apnea and insomnia met criteria for depression. That compared with 22 percent of those with insomnia alone and just 8 percent of those with sleep apnea alone.
That gradient captures something most of us see every week but rarely name. The patient who comes to me on referral has usually cycled through two or three antidepressants without lasting benefit. The chart reads as treatment resistance.
But when the conversation turns to sleep, a different picture often emerges: loud snoring and pauses in breathing that a partner has noticed, or months of lying awake at 3 a.m. long after the mood symptoms were supposed to lift. Before anyone reaches for a third drug, it is worth asking whether an untreated sleep disorder is doing the heavy lifting.
Why sleep disorders look like depression
Sleep apnea and insomnia masquerade as depression because they share its vocabulary. Fatigue, poor concentration, irritability, low mood, and daytime sleepiness are common to all three. Up to 90 percent of people with depression report a sleep complaint, so the overlap is easy to attribute entirely to the mood disorder.
Real physician voices, twice a week
Free, and one click to unsubscribe.
The relationship runs deeper than overlap. Obstructive sleep apnea roughly doubles the risk of developing depression. In long-term data, insomnia, short sleep, apnea, and a disrupted body clock each independently predict later depression, with persistent insomnia conferring more than a two-fold risk.
Just as important for the physician writing the prescriptions, insomnia that lingers after mood symptoms improve predicts relapse and recurrence. The severity of insomnia tracks with poorer response to antidepressants, higher dropout, and lower remission rates. Unrecognized sleep problems do not just mimic depression. They hold it in place.
A 60-second screen
None of this requires a sleep lab to catch in the office. A 60-second screen covers most of the ground.
For sleep apnea, the STOP-BANG questionnaire asks about:
- Snoring
- Tiredness
- Observed pauses in breathing
- High blood pressure
- BMI
- Age over 50
- Neck circumference over 40 cm
- Male sex
It is simple, validated in primary care, and highly sensitive, exceeding 90 percent for moderate-to-severe disease. A low score is reassuring, and a high score warrants home testing or a sleep referral.
For insomnia, two questions do most of the work. Over the last two weeks, has it taken more than 30 minutes to fall asleep, or has the patient been awake for long stretches during the night, most nights?
When a bed partner is available, their account of snoring or breathing pauses is often more reliable than the patient’s. Positive answers on either front should change the plan before the next prescription.
Think twice before adding a sleeping pill
When insomnia is the problem, the instinct to add a sleeping pill deserves a second look. In a nationwide cohort of patients with depression and insomnia followed for a decade, higher doses of sleep medication predicted both a later diagnosis of a sleep-related breathing disorder and worse depression outcomes, including more difficult-to-treat illness. That is a particular hazard if hidden sleep apnea is being sedated rather than treated.
Cognitive behavioral therapy for insomnia (CBT-I) is the better first move. It produces more durable remission than sleeping pills and improves depressive symptoms beyond sleep itself. In older adults with insomnia, it cut the risk of new and recurrent depression by roughly half.
Screen the sleep first
The practical message for primary care is not that antidepressants fail. It is that depression stalled on a foundation of untreated sleep apnea or insomnia is unlikely to be rescued by a third drug.
Screen the sleep first, treat what you find, and save the next medication change for a patient whose nights are already accounted for.
Ravi Singareddy is the founder and medical director of Empower Psychiatry & Sleep in north metro Atlanta, where he leads an interventional psychiatry practice offering transcranial magnetic stimulation (TMS) and Spravato (esketamine) for treatment-resistant depression. Double board-certified in psychiatry and sleep medicine, he brings more than two decades of clinical and academic experience to patients who haven’t found relief with medications alone. He is affiliated with Emory Healthcare.
His interest in neuromodulation dates back to his years as associate professor of psychiatry at Penn State College of Medicine. There, he taught annually on vagus nerve stimulation and novel depression therapies, and he published on long-term combined electroconvulsive therapy and vagus nerve stimulation in the American Journal of Psychiatry. He has authored numerous peer-reviewed papers on sleep disorders, insomnia, anxiety, and depression, with work appearing in Sleep, the Journal of Clinical Sleep Medicine, and Psychiatry Research.
Singareddy is a Fellow of the American Psychiatric Association and the American Academy of Sleep Medicine and practices measurement-based care, tracking outcomes to guide every treatment decision. He shares updates on Instagram.
